Interventions for guttate psoriasis

[1]  D. Wonderling,et al.  Topical therapies for the treatment of plaque psoriasis: systematic review and network meta‐analyses , 2013, The British journal of dermatology.

[2]  Jun Yan,et al.  New insights of T cells in the pathogenesis of psoriasis , 2012, Cellular and Molecular Immunology.

[3]  H. Kwon,et al.  Epidemiology and clinical features of pediatric psoriasis in tertiary referral psoriasis clinic , 2012, The Journal of dermatology.

[4]  C. Griffiths,et al.  Antistreptococcal interventions for guttate and chronic plaque psoriasis: a summarised Cochrane review , 2012 .

[5]  D. Battafarano,et al.  Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. , 2010, Seminars in arthritis and rheumatism.

[6]  H. Ko,et al.  Clinical course of guttate psoriasis: Long‐term follow‐up study , 2010, The Journal of dermatology.

[7]  C. Griffiths,et al.  Definition of treatment goals for moderate to severe psoriasis: a European consensus , 2010, Archives of Dermatological Research.

[8]  K. Yan,et al.  Foxp3+ regulatory T cells and related cytokines differentially expressed in plaque vs. guttate psoriasis vulgaris , 2010, The British journal of dermatology.

[9]  Jan D Bos,et al.  How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. , 2010, The Journal of investigative dermatology.

[10]  M. Lebwohl,et al.  Ustekinumab improves health‐related quality of life in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 1 trial , 2010, The British journal of dermatology.

[11]  J. Saurat,et al.  Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION) , 2007, The British journal of dermatology.

[12]  F. Granath,et al.  Psoriasis phenotype at disease onset: clinical characterization of 400 adult cases. , 2005, The Journal of investigative dermatology.

[13]  Yongqiang Jiang,et al.  Acute Guttate Psoriasis Patients Have Positive Streptococcus Hemolyticus Throat Cultures and Elevated Antistreptococcal M6 Protein Titers , 2005, The Journal of dermatology.

[14]  A. Gottlieb,et al.  Etanercept as monotherapy in patients with psoriasis. , 2003, The New England journal of medicine.

[15]  M. Lebwohl,et al.  An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. , 2003, Archives of dermatology.

[16]  M. Lebwohl,et al.  Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. , 2003, Journal of the American Academy of Dermatology.

[17]  J. Kere,et al.  Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. , 2003, The Journal of investigative dermatology.

[18]  W. Gulliver,et al.  A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. , 2002, Journal of the American Academy of Dermatology.

[19]  C. Owen,et al.  A systematic review of treatments for guttate psoriasis , 2001, The British journal of dermatology.

[20]  U. Chaudhari,et al.  Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial , 2001, The Lancet.

[21]  V. Ho,et al.  Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. , 2001, Journal of the American Academy of Dermatology.

[22]  L. Naldi,et al.  Family history of psoriasis, stressful life events, and recent infectious disease are risk factors for a first episode of acute guttate psoriasis: results of a case-control study. , 2001, Journal of the American Academy of Dermatology.

[23]  C. Griffiths,et al.  Interventions for guttate psoriasis. , 2000, The Cochrane database of systematic reviews.

[24]  J. Koo,et al.  A randomized, double‐blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis , 1998, The British journal of dermatology.

[25]  E. García-Latorre,et al.  Autoantibodies to autologous skin in guttate and plaque forms of psoriasis and cross‐reaction of skin antigens with streptococcal antigens , 1998, International journal of dermatology.

[26]  G. Krueger,et al.  Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. , 1997, Journal of the American Academy of Dermatology.

[27]  L Timmermann,et al.  The mechanism of action of cyclosporin A and FK506. , 1996, Clinical immunology and immunopathology.

[28]  R. Chalmers,et al.  How great is the risk of further psoriasis following a single episode of acute guttate psoriasis? , 1996, Archives of dermatology.

[29]  D. Leung,et al.  A potential role for superantigens in the pathogenesis of psoriasis. , 1993, The Journal of investigative dermatology.

[30]  L. Dubertret,et al.  Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris. A randomized, double-blind, right/left comparative, vehicle-controlled study. , 1992, Journal of the American Academy of Dermatology.

[31]  T. Hamilton,et al.  Acitretin improves psoriasis in a dose-dependent fashion. , 1988, Journal of the American Academy of Dermatology.

[32]  J. H. Roger,et al.  HL‐A antigens in patients with guttate psoriasis , 1976, The British journal of dermatology.

[33]  A. Gottlieb,et al.  Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. , 2010, Journal of the American Academy of Dermatology.

[34]  B. Strober,et al.  Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. , 2008, Journal of the American Academy of Dermatology.

[35]  J. Quell,et al.  Calcipotriene ointment 0.005% for psoriasis: a safety and efficacy study. Calcipotriene Study Group. , 1995, Journal of the American Academy of Dermatology.

[36]  R. Chalmers,et al.  The role of streptococcal infection in the initiation of guttate psoriasis. , 1992, Archives of dermatology.

[37]  U. Mrowietz,et al.  Cyclosporine in psoriasis: a multicenter dose-finding study in severe plaque psoriasis. The German Multicenter Study. , 1992, Journal of the American Academy of Dermatology.

[38]  Pettit Jh.  Oral retinoid for psoriasis. A report of a double blind study. , 1979 .